title: An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.
abstract: OBJECTIVE
  To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever.
  
  
  METHODS
  A randomized, open-label, active control trial with two parallel arms.
  
  
  METHODS
  Emergency Room and Outpatient Clinics in Patan Hospital, Lagankhel, Lalitpur, Nepal.
  
  
  METHODS
  Patients with clinically diagnosed uncomplicated enteric fever meeting the inclusion criteria.
  
  
  METHODS
  Patients were allocated to receive one of two drugs, Gatifloxacin or Cefixime. The dosages used were Gatifloxacin 10 mg/kg, given once daily for 7 days, or Cefixime 20 mg/kg/day given in two divided doses for 7 days.
  
  
  METHODS
  The primary outcome measure was fever clearance time. The secondary outcome measure was overall treatment failure (acute treatment failure and relapse).
  
  
  RESULTS
  Randomization was carried out in 390 patients before enrollment was suspended on the advice of the independent data safety monitoring board due to significant differences in both primary and secondary outcome measures in the two arms and the attainment of a priori defined endpoints. Median (95% confidence interval) fever clearance times were 92 hours (84-114 hours) for gatifloxacin recipients and 138 hours (105-164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545-3.051], p<0.0001). 19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 - 0.237], p<0.001). Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%-50.2%) in the cefixime group and 3.5% (2.2%-11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025-0.280], p<0.0001). There was one death in the cefixime group.
  
  
  CONCLUSIONS
  Based on this study, gatifloxacin is a better treatment for uncomplicated enteric fever as compared to cefixime.
  
  
  BACKGROUND
  Current Controlled Trials ISRCTN75784880.
authors.affiliation: Patan Hospital, Lagankhel, Lalitpur, Nepal.
authors.forename: Anil
authors.initials: A
authors.lastname: Pandit
authors.forename: Amit
authors.initials: A
authors.lastname: Arjyal
authors.forename: Jeremy N
authors.initials: JN
authors.lastname: Day
authors.forename: Buddhi
authors.initials: B
authors.lastname: Paudyal
authors.forename: Sabina
authors.initials: S
authors.lastname: Dangol
authors.forename: Mark D
authors.initials: MD
authors.lastname: Zimmerman
authors.forename: Bharat
authors.initials: B
authors.lastname: Yadav
authors.forename: Kasia
authors.initials: K
authors.lastname: Stepniewska
authors.forename: James I
authors.initials: JI
authors.lastname: Campbell
authors.forename: Christiane
authors.initials: C
authors.lastname: Dolecek
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Farrar
authors.forename: Buddha
authors.initials: B
authors.lastname: Basnyat
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D020682:Cefixime / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011379:Prognosis; D012475:Salmonella / Q000145:classification / Q000187:drug effects; D012480:Salmonella Infections / Q000188:drug therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014435:Typhoid Fever / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D020682:Cefixime; D000077734:Gatifloxacin